A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Cited by (1,095)

Items 701–800 of 1,095

1. Zinc in the Glutamatergic Theory of Depression
   Katarzyna Młyniec · 2015 · Current Neuropharmacology
2. Orphan receptor GPR158 controls stress-induced depression
   Laurie P. Sutton, Cesare Orlandi, Chenghui Song, Won Chan Oh, Brian S. Muntean, Keqiang Xie, Alice Filippini, Xiangyang Xie, Rachel Satterfield, Jazmine D. W. Yaeger et al. · 2018 · eLife
3. The Ups and Downs of Modelling Mood Disorders in Rodents
   David Anthony Slattery, John F. Cryan · 2014 · ILAR Journal
4. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression
   Zoë A. Hughes, S.J. Neal, Daniel L. Smith, Stacey J. Sukoff Rizzo, Claudine M. Pulicicchio, Susan M. Lotarski, Shiao-Ping Lu, Jason M. Dwyer, Julie A. Brennan, Michael A. Olsen et al. · 2012 · Neuropharmacology
5. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial
   Gálvez, Verònica, Li, Adrienne, Huggins, Christina, Glue, Paul, Martin, Donel, Somogyi, Andrew A, Alonzo, Angelo, Rodgers, Anthony, Mitchell, Philip B, Loo, Colleen K · 2018 · Journal of Psychopharmacology
6. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
   Farmer, Cristan A., Gilbert, Jessica R., Moaddel, Ruin, George, Jomy, Adeojo, Lilian, Lovett, Jacqueline, Nugent, Allison C., Kadriu, Bashkim, Yuan, Peixiong, Gould, Todd D. et al. · 2020 · Neuropsychopharmacology
7. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques
   Yamanaka, H, Yokoyama, C, Mizuma, H, Kurai, S, Finnema, S J, Halldin, C, Doi, H, Onoe, H · 2014 · Translational Psychiatry
8. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double‐blind, placebo‐controlled, proof‐of‐concept trial
   Domany, Yoav, Shelton, Richard C., McCullumsmith, Cheryl B. · 2020 · Depression and Anxiety
9. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
   Kim, Yong-Ku, Na, Kyoung-Sae · 2016 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
10. Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model
    H-L Sun, Z-Q Zhou, G.-F. Zhang, Chun Yang, X-M Wang, J-C Shen, Kenji Hashimoto, J-J Yang · 2016 · Translational Psychiatry
11. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
    Holmes, Sophie E., Finnema, Sjoerd J., Naganawa, Mika, DellaGioia, Nicole, Holden, Daniel, Fowles, Krista, Davis, Margaret, Ropchan, Jim, Emory, Paul, Ye, Yunpeng et al. · 2022 · Molecular Psychiatry
12. Prefrontal changes in the glutamate-glutamine cycle and neuronal/glial glutamate transporters in depression with and without suicide
    Zhao, J., Verwer, R.W.H., van Wamelen, D.J., Qi, X.-R., Gao, S.-F., Lucassen, P.J., Swaab, D.F. · 2016 · Journal of Psychiatric Research
13. Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
    Morris, Patrick J., Moaddel, Ruin, Zanos, Panos, Moore, Curtis E., Gould, Todd, Zarate, Carlos A., Thomas, Craig J. · 2017 · Organic Letters
14. Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide–cGMP and PI3K/mTOR pathways
    Luis E.B. Bettio, Mauricio Peña Cunha, Josiane Budni, Francis L. Pazini, Ágatha Oliveira‐Giacomelli, André Roberto Da Silva Colla, Ana Lúcia S. Rodrigues · 2012 · Behavioural Brain Research
15. Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression
    Ming Guo, Y Lu, J C Garza, Yuqing Li, Streamson C. Chua, W Zhang, Bai Lu, X-Y Lu · 2012 · Translational Psychiatry
16. The pharmacological properties of antidepressants
    Giorgio Racagni, Maurizio Popoli · 2010 · International Clinical Psychopharmacology
17. Activation of AMPA Receptors Mediates the Antidepressant Action of Deep Brain Stimulation of the Infralimbic Prefrontal Cortex
    Laura Jiménez-Sánchez, Anna Castañé, Laura Pérez-Caballero, Marc Grifoll, Xavier López-Gil, Leticia Campa, Mireia Galofré, Esther Berrocoso, Albert Adell · 2015 · Cerebral Cortex
18. Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial
    Smith, Eric G., Deligiannidis, Kristina M., Ulbricht, Christine M., Landolin, Chelsea S., Patel, Jayendra K., Rothschild, Anthony J. · 2013 · The Journal of Clinical Psychiatry
19. Ketamine and selective activation of parvalbumin interneurons inhibit stress-induced dendritic spine elimination
    Ng, Lhotse Hei Lui, Huang, Yuhua, Han, Lei, Chang, Raymond Chuen-Chung, Chan, Ying Shing, Lai, Cora Sau Wan · 2018 · Translational Psychiatry
20. (R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
    Zanos, Panos, Highland, Jaclyn N., Liu, Xin, Troppoli, Timothy A., Georgiou, Polymnia, Lovett, Jacqueline, Morris, Patrick J., Stewart, Brent W., Thomas, Craig J., Thompson, Scott M. et al. · 2019 · British Journal of Pharmacology
21. Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research
    Chiara Fabbri, Giulia di Girolamo, Alessandro Serretti · 2013 · American Journal of Medical Genetics Part B Neuropsychiatric Genetics
22. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway
    Morgana Moretti, Josiane Budni, Andiara E. Freitas, Priscila Batista da Rosa, Ana Lúcia S. Rodrigues · 2013 · Journal of Psychiatric Research
23. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation
    Maxine X. Patel, Faisil Nasim Sethi, Thomas RE Barnes, Roland Dix, Luiz Dratcu, Bernard A Foex, Marina Garriga, Julie C Haste, Kai G. Kahl, Anne R. Lingford-Hughes et al. · 2018 · Journal of Psychopharmacology
24. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
    Fogaça, Manoela V., Fukumoto, Kenichi, Franklin, Tina, Liu, Rong-Jian, Duman, Catharine H., Vitolo, Ottavio V., Duman, Ronald S. · 2019 · Neuropsychopharmacology
25. Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder
    Yanni Zhan, Yanling Zhou, Wei Zheng, Weijian Liu, Chengyu Wang, Xiaofeng Lan, Xiurong Deng, Yan Xu, Bin Zhang, Yuping Ning · 2020 · Translational Psychiatry
26. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
    Price, Rebecca B., Kissel, Nicholas, Baumeister, Andrew, Rohac, Rebecca, Woody, Mary L., Ballard, Elizabeth D., Zarate, Carlos A., Deakin, William, Abdallah, Chadi G., Feder, Adriana et al. · 2022 · Molecular Psychiatry
27. State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression
    Marion Kühn, F Mainberger, Bernd Feige, Jonathan Gabriel Maier, Volker Mall, Nicolai H Jung, Janine Reis, Stefan Klöppel, Claus Normann, Christoph Nissen · 2015 · Neuropsychopharmacology
28. The PSD-95/nNOS complex: New drugs for depression?
    Marika V. Doucet, Andrew Harkin, Kumlesh Kumar Dev · 2011 · Pharmacology & Therapeutics
29. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure
    Dwyer, Jason M, Lepack, Ashley E, Duman, Ronald S · 2013 · Journal of Molecular Psychiatry
30. Oral ketamine for the treatment of pain and treatment-resistant depression
    Schoevers, Robert A., Chaves, Tharcila V., Balukova, Sonya M., Rot, Marije aan Het, Kortekaas, Rudie · 2016 · British Journal of Psychiatry
31. Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
    López-Gil, Xavier, Jiménez-Sánchez, Laura, Campa, Leticia, Castro, Elena, Frago, Clara, Adell, Albert · 2019 · ACS Chemical Neuroscience
32. Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions
    Giacomo Salvadore, Jaskaran B. Singh · 2013 · CNS Neuroscience & Therapeutics
33. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects
    Ruin Moaddel, Michelle D Shardell, Mohammed Khadeer, Jacqueline Lovett, Bashkim Kadriu, Sarangan Ravichandran, Patrick J. Morris, Peixiong Yuan, Craig J. Thomas, Todd D. Gould et al. · 2018 · Psychopharmacology
34. Novel antidepressant drugs: Beyond monoamine targets
    Xénia Gonda, Péter Döme, Joanna Caroline Neill, Frank I. Tarazi · 2021 · CNS Spectrums
35. The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
    Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles F. Saylor et al. · 2024 · Current Neuropharmacology
36. Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats
    Gislaine Z. Réus, Helena M. Abelaira, Roberto B. Stringari, Gabriel R. Fries, Flávio Pereira Kapczinski, João Quevedo · 2012 · Metabolic Brain Disease
37. A single dose of S ‐ketamine induces long‐term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation
    Gislaine Z. Réus, Anelise Scussel Carlessi, Stephanie E. Titus, Helena M. Abelaira, Zuleide Maria Ignácio, Jaine R. da Luz, Beatriz I. Matias, Lívia Bruchchen, Driélly Florentino, Andriele Aparecida da Silva Vieira et al. · 2015 · Developmental Neurobiology
38. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
    Ballard, Elizabeth D., Luckenbaugh, David A., Richards, Erica M., Walls, Tessa L., Brutsché, Nancy E., Ameli, Rezvan, Niciu, Mark J., Vande Voort, Jennifer L., Zarate, Carlos A. · 2015 · Journal of Psychiatric Research
39. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
    Zhu, Weili, Ding, Zengbo, Zhang, Yinan, Shi, Jie, Hashimoto, Kenji, Lu, Lin · 2016 · Neuroscience Bulletin
40. Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors
    Lazarevic, Vesna, Yang, Yunting, Flais, Ivana, Svenningsson, Per · 2021 · Molecular Psychiatry
41. Dose- and Exposure-Response to Ketamine in Depression
    Paul Glue, Abhishek Gulati, Martin Le Nedelec, Stephen Brent Duffull · 2011 · Biological Psychiatry
42. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department
    Gregory Luke Larkin, Annette L. Beautrais, Robert Turelli, Gerard Sanacora, Seth M. Powsner, Melanie J. Lippmann, John Harrison Krystal · 2011 · European Psychiatry
43. Ketamine administration reduces amygdalo‐hippocampal reactivity to emotional stimulation
    Scheidegger, Milan, Henning, Anke, Walter, Martin, Lehmann, Mick, Kraehenmann, Rainer, Boeker, Heinz, Seifritz, Erich, Grimm, Simone · 2016 · Human Brain Mapping
44. The Role of GluN2A and GluN2B Subunits on the Effects of NMDA Receptor Antagonists in Modeling Schizophrenia and Treating Refractory Depression
    Laura Jiménez-Sánchez, Leticia Campa, Yves P. Auberson, Albert Adell · 2014 · Neuropsychopharmacology
45. Rapid-acting antidepressant strategies: mechanisms of action
    Bunney, Blynn G., Bunney, William E. · 2012 · The International Journal of Neuropsychopharmacology
46. Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress
    José Amat, Samuel D Dolzani, Scott G. Tilden, John P. Christianson, Kenneth H. Kubala, Kristi L. Bartholomay, Katherine Sperr, Nicholas Ciancio, Linda R. Watkins, Steven F. Maier · 2016 · Journal of Neuroscience
47. Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes
    Vanja Đurić, Ronald S. Duman · 2012 · Cellular and Molecular Life Sciences
48. A Hypothesized Role for Dendritic Remodeling in the Etiology of Mood and Anxiety Disorders
    Jack M. Gorman, John P. Docherty · 2010 · Journal of Neuropsychiatry
49. Hippocampal volume and the rapid antidepressant effect of ketamine
    Abdallah, Chadi G, Salas, Ramiro, Jackowski, Andrea, Baldwin, Philip, Sato, João R, Mathew, Sanjay J · 2015 · Journal of Psychopharmacology
50. Pharmacology of Sedative-Analgesic Agents: Dexmedetomidine, Remifentanil, Ketamine, Volatile Anesthetics, and the Role of Peripheral Mu Antagonists
    Oliver P. F. Panzer, Vivek K. Moitra, Robert N. Sladen · 2011 · Anesthesiology Clinics
51. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant
    Samuel T. Wilkinson, Cristan Farmer, Elizabeth D. Ballard, Sanjay J. Mathew, Michael F. Grunebaum, James W. Murrough, P. Šóš, Gang Wang, Ralitza V. Gueorguieva, Carlos A. Zarate · 2019 · Neuropsychopharmacology
52. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
    Joanna Kryst, Paweł Kawalec, Andrzej Pilc · 2019 · Expert Opinion on Pharmacotherapy
53. The Effects of General Anesthetics on Synaptic Transmission
    Xuechao Hao, Mengchan Ou, Donghang Zhang, Wenling Zhao, Yaoxin Yang, Jin Liu, Hui Yang, Tao Zhu, Yu Li, Cheng Zhou · 2020 · Current Neuropharmacology
54. Are Essential Trace Elements Effective in Modulation of Mental Disorders? Update and Perspectives
    Mehran Shayganfard · 2021 · Biological Trace Element Research
55. A behavioral and molecular analysis of ketamine in zebrafish
    Sherry M. Zakhary, Diana Ayubcha, Farah Ansari, Kiran Kamran, Mehwish Karim, Joerg R. Leheste, Judith M. Horowitz, German Torres · 2010 · Synapse
56. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23
    Satoshi Deyama, Kento Shimoda, Hiroe Suzuki, Yuka Ishikawa, Kohei Ishimura, Hayato Fukuda, Natsuko HitoraーImamura, Soichiro Ide, Masamichi Satoh, Katsuyuki Kaneda et al. · 2017 · Psychopharmacology
57. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale
    Gerrit Ian van Schalkwyk, Samuel T. Wilkinson, Larry Davidson, Wendy K. Silverman, Gerard Sanacora · 2017 · Journal of Affective Disorders
58. Targeting inflammation: a potential approach for the treatment of depression
    Shvetank Bhatt, Thangaraj Devadoss, Niraj Kumar Jha, Moushumi Baidya, Gaurav Gupta, Dinesh Kumar Chellappan, Sachin Kumar Singh, Kamal Dua · 2022 · Metabolic Brain Disease
59. Glia in the cytokine-mediated onset of depression: fine tuning the immune response
    Wendy Karen Jo, Yuanyuan Zhang, Hinderk Meiners Emrich, Detlef E. Dietrich · 2015 · Frontiers in Cellular Neuroscience
60. Aripiprazole in the Treatment of Depressive and Anxiety Disorders
    Chi‐Un Pae, Alessandro Serretti, Ashwin A. Patkar, Praksh S. Masand · 2008 · CNS Drugs
61. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant–anticonvulsant action
    Ilse Julia Smolders, Ralph Clinckers, Alfred Meurs, Dimitri De Bundel, Jeanelle Portelli, Guy Ebinger, Yvette Madeleine Michotte · 2008 · Neuropharmacology
62. Yueju Pill Rapidly Induces Antidepressant-Like Effects and Acutely Enhances BDNF Expression in Mouse Brain
    Wenda Xue, Xin‐Fu Zhou, Nan Yi, Lihua Jiang, Weiwei Tao, Runjie Wu, Dan Wang, Jingjing Jiang, Xiaoyin Ge, Yuyue Wang et al. · 2013 · Evidence-based Complementary and Alternative Medicine
63. Examining the use of tramadol hydrochloride as an antidepressant.
    Justin Barber · 2011 · Experimental and Clinical Psychopharmacology
64. Decreased Glutamate/Glutamine Levels May Mediate Cytidine’s Efficacy in Treating Bipolar Depression: A Longitudinal Proton Magnetic Resonance Spectroscopy Study
    Sujung J. Yoon, In Kyoon Lyoo, Charlotte A. Haws, Tae Suk Kim, Bruce M. Cohen, Perry Franklin Renshaw · 2009 · Neuropsychopharmacology
65. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor
    Kinga Sałat, Agata Siwek, Gabriela Starowicz, Tadeusz Librowski, Gabriel Nowak, Urszula Drabik, Ryszard Gajdosz, Piotr Popik · 2015 · Neuropharmacology
66. mGlu2/3 Receptor Antagonists as Novel Antidepressants
    Chaki, Shigeyuki · 2017 · Trends in Pharmacological Sciences
67. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity
    Kang, Melody J. Y., Hawken, Emily, Vazquez, Gustavo Hector · 2022 · Frontiers in Psychiatry
68. Ketamine, Sleep, and Depression: Current Status and New Questions
    Duncan, Wallace C., Zarate, Carlos A. · 2013 · Current Psychiatry Reports
69. Experimental medication treatment approaches for depression
    D. Ionescu, George I. Papakostas · 2017 · Translational Psychiatry
70. A Major Role for the Lateral Habenula in Depressive Illness: Physiologic and Molecular Mechanisms
    Philip W. Gold, Bashkim Kadriu · 2019 · Frontiers in Psychiatry
71. Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges
    Ana Paula Vargas Visentin, Rafael Colombo, Ellen Scotton, Débora Soligo Fracasso, Adriane Ribeiro Rosa, Cátia Santos Branco, Mirian Mendonça Salvador · 2020 · Oxidative Medicine and Cellular Longevity
72. Neuroimmunology of depression
    Erika Sarno, Adam James Moeser, Alfred Jay Robison · 2021 · Advances in pharmacology
73. Periodic and aperiodic changes to cortical EEG in response to pharmacological manipulation
    Sofia V. Salvatore, Peter M. Lambert, Ann M. Benz, Nicholas R. Rensing, Michael Wong, Charles F. Zorumski, Steven J. Mennerick · 2024 · Journal of Neurophysiology
74. Noradrenergic Dysfunction in Depression and Suicide
    Michelle Chandley, Gregory A. Ordway · 2012 · Frontiers in neuroscience
75. Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis
    Michael Tilghman Treadway, Diego A. Pizzagalli · 2014 · Biology of Mood & Anxiety Disorders
76. The influence of ketamine on drug discovery in depression
    Kraus, Christoph, Wasserman, Daniel, Henter, Ioline D., Acevedo-Diaz, Elia, Kadriu, Bashkim, Zarate, Carlos A. · 2019 · Drug Discovery Today
77. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons
    El Iskandrani, Kareem S, Oosterhof, Chris A, El Mansari, Mostafa, Blier, Pierre · 2015 · Journal of Psychopharmacology
78. Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy
    Stuart, Sarah A, Butler, Paul, Munafò, Marcus R, Nutt, David J, Robinson, Emma SJ · 2015 · Neuropsychopharmacology
79. Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development
    Frye, Mark A., Blier, Pierre, Tye, Susannah J. · 2015 · Journal of Clinical Psychopharmacology
80. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action
    Erik H.F. Wong, Frank I. Tarazi, Mohammed Shahid · 2010 · Pharmacology & Therapeutics
81. Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet
    Anette Kjellgren, Kristoffer Jonsson · 2013 · Journal of Psychoactive Drugs
82. Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
    Molly C. Kalmoe, Alvin M. Janski, Charles F. Zorumski, Peter Nägele, Ben Julian A. Palanca, Charles R. Conway · 2020 · Journal of the Neurological Sciences
83. Rapid-acting antidepressants
    Jeffrey M. Witkin, Anna E. Martin, Lalit Kumar Golani, Nina Z. Xu, Jodi L. Smith · 2019 · Advances in pharmacology
84. Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice
    Radhika Rawat, Elif Tunc‐Ozcan, Tammy L. McGuire, Chian‐Yu Peng, John A. Kessler · 2022 · Nature Communications
85. A defined network of fast-spiking interneurons in orbitofrontal cortex: responses to behavioral contingencies and ketamine administration
    Michael C. Quirk · 2009 · Frontiers in Systems Neuroscience
86. Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims
    Magdalena Sowa-Kućma, Bernadeta Szewczyk, Krystyna Sadlik, Wojciech Piekoszewski, Franciszek Trela, Włodzimierz Opoka, Ewa Poleszak, Andrzej Pilc, Gabriel Nowak · 2013 · Journal of Affective Disorders
87. Depression in epilepsy
    Marco Mula · 2017 · Current Opinion in Neurology
88. Effect of Ketamine on LTP and NMDAR EPSC in Hippocampus of the Chronic Social Defeat Stress Mice Model of Depression
    Yu Yang, Weina Ju, Haining Zhang, Li Sun · 2018 · Frontiers in Behavioral Neuroscience
89. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists
    Pozzi, Laura, Dorocic, Iskra Pollak, Wang, Xinming, Carlén, Marie, Meletis, Konstantinos · 2014 · PLoS ONE
90. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
    Huang, Yu-Jhen, Lane, Hsien-Yuan, Lin, Chieh-Hsin · 2017 · Neural Plasticity
91. Investigational drugs in recent clinical trials for treatment-resistant depression
    Ricardo Pablo Garay, Carlos A. Zarate, Thomas Charpeaud, Leslie Citrome, Christoph Ulrich Correll, Ahcène Hameg, Pierre‐Michel Llorca · 2017 · Expert Review of Neurotherapeutics
92. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
    John Harrison Krystal, Alfred P. Kaye, Sarah Jefferson, Matthew J. Girgenti, Samuel T. Wilkinson, Gerard Sanacora, Irina Esterlis · 2023 · Proceedings of the National Academy of Sciences
93. The hidden third: improving outcome in treatment-resistant depression
    Thomas Eduard Schlaepfer, Hans Ågren, Palmiero Monteleone, Cristòbal Gastó, William Pitchot, F. Rouillon, David Nutt, Siegfried F. Kasper · 2012 · Journal of Psychopharmacology
94. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial
    Kari R. Nations, Peter Dogterom, Roberta Bursi, Jacques Schipper, Scott D. Greenwald, David Zraket, Lev Gertsik, Jack Johnstone, Allen Ting Chun Lee, Yogesh Pande et al. · 2012 · Journal of Psychopharmacology
95. Chronic ketamine use increases serum levels of brain-derived neurotrophic factor
    Valerio Ricci, Giovanni Martinotti, Francesca Gelfo, Federico Tonioni, Carlo Caltagirone, Pietro Bria, Francesco Angelucci · 2010 · Psychopharmacology
96. A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
    Lee, Yena, Syeda, Kahlood, Maruschak, Nadia A., Cha, Danielle S., Mansur, Rodrigo B., Wium-Andersen, Ida K., Woldeyohannes, Hanna O., Rosenblat, Joshua D., McIntyre, Roger S. · 2016 · Journal of Clinical Psychopharmacology
97. Single bolus low-dose of ketamine does not prevent postpartum depression: a randomized, double-blind, placebo-controlled, prospective clinical trial
    Yang Y. Xu, Yuantao Li, Xiaolei Huang, Daili Chen, Bao-Zuan She, Daqing Ma · 2017 · Archives of Gynecology and Obstetrics
98. Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales
    Elizabeth D. Ballard, Julia S. Yarrington, Cristan Farmer, Marc S. Lener, Bashkim Kadriu, Níall Lally, Deonte Williams, Rodrigo Machado‐Vieira, Mark J. Niciu, Lawrence Park et al. · 2018 · Journal of Affective Disorders
99. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
    Randall L. Morrison, Maggie M Fedgchin, Jaskaran B. Singh, Joop van Gerven, Rob G. J. A. Zuiker, Kyoung Soo Lim, Peter D van der Ark, Ewa Wajs, Liwen Xi, Peter Zannikos et al. · 2018 · Psychopharmacology
100. S-Ketamine Reverses Hippocampal Dendritic Spine Deficits in Flinders Sensitive Line Rats Within 1 h of Administration
     Treccani, Giulia, Ardalan, Maryam, Chen, Fenghua, Musazzi, Laura, Popoli, Maurizio, Wegener, Gregers, Nyengaard, Jens Randel, Müller, Heidi Kaastrup · 2019 · Molecular Neurobiology